A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients

• Status: Terminated
• Trial end date: 2005-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To define the safety of cytotoxic T lymphocytes (CTLs) generated from sibling-supplied dendritic cells and lymphocytes and infused into an HIV-infected patient. To determine the efficacy of these CTLs in helping the immune system to fight HIV.

With lower CD4 counts, HIV-infected patients may not be able to produce dendritic cells and lymphocytes, special types of immune cells that generate HIV-specific CTLs. Infusion of CTLs generated from the dendritic cells and lymphocytes of an HIV-negative sibling may enable the body to recognize HIV more readily and increase immune response against the virus.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Criteria

Inclusion Criteria

Patients must have:

• HLA A2+.

• Other HLA matching with sibling.

• CD4 count 100-350 cells/mm3.

• No active opportunistic infection or malignancy (other than cutaneous Kaposi's sarcoma).

• Current stable antiviral regimen.

• Normal lab values and chest x-ray.

Donor siblings must have:

• HLA A2+.

• HIV negativity.

• Good venous access.

• Ability to donate on multiple occasions.

• Negative status for hepatitis B and C.

Exclusion Criteria

Concurrent Medication:

Excluded:

• Immunomodulators.

• Cytokines.

• Systemic steroids.

• IV pentamidine.

• Investigational drugs.